Abstract
Statins reduce risk of major adverse cardiovascular events (MACE) in women and men; whether the same holds true for PCSK9 inhibition is uncertain. The ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to high-intensity or maximum-tolerated statin treatment, in 4,762 women and 14,162 men
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
